The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)

Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01796691

Acronym

BOCLA-Mort

Enrollment

600

Registered

2013-02-22

Start date

2009-01-31

Completion date

2013-02-28

Last updated

2013-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Clopidogrel, aspirin, low response, platelet aggregation, Acute Coronary Syndrome, Coronary Stent Implantation

Brief summary

Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.

Detailed description

The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* coronary stent implantation

Exclusion criteria

* no consent

Design outcomes

Primary

Measure	Time frame	Description
Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction)	Follow up for up to 12 months (retrospective analysis)	MACE-rate

Countries

Germany

Outcome results